REGENXBIO is a gene therapy company built around its NAV AAV (adeno-associated virus) vector platform for delivering genetic medicines. It develops its own pipeline—often focused on retinal, neuromuscular, and metabolic diseases—and licenses vector technology and manufacturing know-how to other biopharma partners. The model mixes product development with platform and licensing economics rather than traditional small-molecule drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 21.4 | — | -70.9 | — |
| Q3 2025 | 29.7 | — | -61.9 | — |
| Q4 2025 | 30.3 | — | -67.2 | — |
| Q1 2026 | 6.4 | — | -90 | — |
| Q2 2026 | 108 | 405.7% | 22.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: WhiteFiber, Inc. (WYFI), Sight Sciences, Inc. (SGHT), NioCorp Developments Ltd. (NB), Arvinas, Inc. (ARVN), Johnson Outdoors Inc. (JOUT), Industrial Logistics Properties Trust (ILPT)